Prof Tan Eng King

MBBS, MRCP (United Kingdom), FAMS (Neurology), FRCP (Edinburgh)

Deputy Chief Executive Officer＆ Senior Consultant

National Neuroscience Institute

Specialty/Department: Neurology, Neurology

Clinical Interests: Parkinson's Disease, Movement Disorders, General Neurology

Conditions Treated by this Doctor:
Parkinson's Disease and Movement Disorders

Make an Appointment

Clinical Appointments

Senior Consultant Neurology Singapore General Hospital
Deputy Chief Executive Officer＆ Senior Consultant Department of Neurology National Neuroscience Institute

Academic Appointments

Academic Deputy Chair SingHealth Duke-NUS Neuroscience Academic Clinical Programme

Profile

Prof EK Tan is a Deputy Chief Executive Officer (Academic Affairs) and Senior Consultant Neurologist at the National Neuroscience Institute, a Professor at Duke-NUS Medical School and… View More +

Education

Fellow of the Royal College of Physicians (Edinburgh, United Kingdom), 2006
Fellow, Academy of Medicine, Singapore, 2000
United States Medical Licensing Examination (United States), 1997
Member of the Royal Colleges of Physicians (United Kingdom), 1995
Designated Factory Doctor Diploma (Ministry of Health), 1992
Bachelor of Medicine and Bachelor of Surgery (National University of Singapore), 1989

View More +

Professional Appointments and Committee Memberships

Deputy Chief Executive Officer (Academic Affairs), National Neuroscience Institute
Senior Consultant, Department of Neurology, National Neuroscience Institute (NNI@SGH)
Academic Deputy Chair, Academic Affairs, SingHealth Duke-NUS Neuroscience Academic Clinical Programme
Professor, Neuroscience & Behavioural Disorders, Duke-NUS Medical School
Professor, Division of Medicine, Yong Loo Lin School of Medicine, NUS
Honorary Professor, Lee Kong Chian School of Medicine
Co director, USA National Parkinson Foundation Center of Excellence
Guest Professor, Central South University, Changsha, Hunan, China
Associate Designated Institution Officer (ADIO) for Residency, Singhealth
Honorary Secretary, Clinical Neuroscience Society of Singapore, 2004-present
Executive Steering committee, Asian-Oceanic section, International Movement Disorders Society, 2005-7
Chairman, Parkinson’s Disease Clinical Pathway Team, SGH, 2004
Coordinator, NNI sub-committee for research (NNI@SGH), 2003
Member, Pharmacy Naming committee, SGH, 2000/2
Member, SingHealth PET Tender committee, 2002
Executive Member, Clinical Neuroscience Society, 2001/3
Executive Member, Parkinson’s Disease Society, Singapore, 2000-presen
Member, Organising Committee of 2nd ASEAN Neurological Association Neurology Convention, 1997.
Member, Organising Committee of SGH Brain Centre Function, 1995.
Member, Committee of SGH Parkinson’s Disease Support Group, 1995-present
Member, Executive committee of National Parkinson’s Disease Society, 1997/98
Member, SGH Rehabilitation committee, 1996/7
Member, Bishan Health Fair committee, 2000
Member, MCD/SGH Health Screening for the Elderly committee, April 2000
Co-chairman, 1st International PD and Movement Disorder Symposium, Feb 2002
Chairman, SGH PD GP Shared Care committee, July 2002
Vice-chairman, 2nd International PD and Movement Disorder Symposium Dec, 2003
Organising Chairman, 3rd International PD and Movement Disorder Symposium, 2005
Organising Chairman, Movement Disorders Subcommittee, Asian Oceanian Congress of Neurology, 2004
Central organizing committee member, Asian Oceanian Congress of Neurology, 2004
Chairman, National PD Public Forum committee, 2004
Member, Scientific Issues Committee, International Movement Disorders Society, 2007-present
Member, Ministry of Health SAB Research committee, 2007
Chairman of the scientific committee and co-chair organising committee for the International AOPMC meeting, 2007
Scientific co-chair for the 41st Malaysian-Singapore Congress, 2007
Chairman, innovation and advances in medicine, 41st Malaysian-Singapore Congress in 2007
Chairman, Research Committee, National Neuroscience Institute, 2007-2008
Director, Research National Neuroscience Institute, 2010-current
Member, Interim Steering Committee, ASTAR-Duke Partnership on Neuroscience, 2008-9
Selection committee, SingHealth Clinician Sciention committee, NRF-MOH Research Scholarship (PhD), NMRC Fellowship Awards, 2008
Selection panel, Khoos Awards Review Committee, GMS-NUS, 2008
Executive committee, International Movement Disorders Society (AOS), 2007 – 2013
Member, Scientific Issues committee, International Movement Disorders Society, 2007 – 2013
Member, Duke - NUS Graduate Medical School Admissions Committee, 2008 – 2013
Member, Duke - NUS Graduate Medical School Interview Panel, 2008 – current
Member, Duke- NUS Khoo Infrastructure Award (KIA) Oversight Committee, 2009 – 2013
Member, National medical Research Council New Investigator Grants Committee, 2009 – current
Member, Biomedical Research Council Translational Grants Committee, 2009 – 2012
Member, Committee, Clinician Career Model (Research), Singhealth, 2010
Council Member, Academy of Medicine, Singapore, 2010 – present
Abstract reviewer, 136th American Neurological Association Meeting, 2011
Treasurer elect, International Movement Disorders Society (AOS) 2011
Member, Committee, Parkinson’s disease Research group, World Federation of Neurology, 2011 – present
Chairman, Ministry of Health Accreditation of Mentors, Research Units, 2011 – present
Member, NMRC, Clinician Scientist Unit, 2011
Chairman, Chapter of Clinician Scientist, Academy of Medicine, 2012 – 2015
Member NMRC ASTAR Bench and Bedside Review Panel, 2012 – 2016
Member, Congress Scientific Program Committee, International Movement Disorders Society, 2012 – present
Member, ASTAR NRF Healthcare Expert Panel, 2013 – 2015
Academic Vice chair, SingHealth Neuroscience Academic Clinical Programme, 2012 – present
Member, NMRC Awards organising committee, 2014 – present
Member, Genome Institute of Singapore Platform Oversight Committee, 2015 – present
Member, National Health and Biomedical Sciences Open Fund Sub Committee, 2015 – present
Member, Lee Kong Chian School of Medicine, Search Committee for Professor of Anatomy, 2015
Associate Faculty (Senior Group Leader), Genome Institute of Singapore, GIS Partnership Programme, 2015 – 2019
Advisory Panel, Singapore General Hospital Research, 2015 – present
Advisory Panel, Centre for Aging Research and Education (CARE), Duke-NUS, 2015 – present
Member, Continuing Medical Education (CME) Panel, International Movement Disorders Society, 2015 – present
Member, International Dystonia Task Force, International Movement Disorders Society, 2015 – present
Member, International Tremor Task Force, International Movement Disorders Society, 2015 – present
Member, Clinical Research Committee, SGH Department of Clinical Research, 2016 - present
Member, Working Committee for Strategic Thrust #2 “Identify, Develop and Retain Clinician Scientists, Basic Scientists and Research Professionals”, 2016 – present
Clinical Advisory Committee, MOH Chronic Disease Management Programme, 2016 – 2019
Chairman, National Neuroscience and Sensory Disorders Task Force, 2016 – present
Chairman, NMRC ASTAR Bench and Bedside Review Panel, 2016 – present
Advisor, SingHealth Duke-NUS Health Services Research, 2016
Member, Strategic Planning Committee, International Association Parkinsonism and Related Disorders, 2017 – present
Member, Congress Proceedings Committee, International Association Parkinsonism and Related Disorders, 2017 – present
Co-chairman, Open Fund IRG Panel 2016-present
Vice-Chairman SAB Research Committee, 2015-present
Chairman Research Training Review Panel MOH 2016-present
Associate Designated Institutional Official, Singhealth Residency 2014-presentCo-chairman, NMRC Research Training Review Panel 2015-present
Director, Research, National Neuroscience Institute, 2010-2021

View More +

Awards

AOS Ambassador for the 3rd Taiwan International Congress of Parkinson’s Disease and Movement Disorders, International Parkinson and Movement Disorder Society, 2016
SingHealth Duke-NUS Research Team Award, 1st Prize, 2017
Distinguished Member, Japanese Society of Neurology 2016
Yoshikuni Mizuno Award, International Parkinson and Movement Disorder Society – Asian and Oceanian Section (MDS-AOS) 2016
SingHealth Distinguished Team award 2015
STaR Investigator award 2014
SingHealth Distinguished Researcher Award 2011
National Outstanding Clinician Scientist Award 2011
Ministry of Health HMDP clinical fellowship Award in Parkinson’s disease and Movement Disorders 1998/1999.
National Medical Research Council-Singapore Totalisator Board Medical Research Fellowship Award in Neurogenetics 1999.
Commendation for outstanding performance, Baylor College of Medicine, USA 1999
Singapore General Hospital Excellent Publication Award (Gold) 2001
Singapore General Hospital Clinician Scientist Award 2002
National Medical Research Council and Biomedical Research Council Clinician Scientist Award 2005
SingHealth Excellent Researcher Award 2005
National Medical Research Council Clinician Scientist Award 2008
Duke NUS Khoo Investigator Excellence Award 2008
Singapore General Hospital Service Quality Excellence Award 2010
Elected Member, American Neurological Association, 2010

View More +

Research Interests

Clinical, neuroimaging and translational studies in movement disorders including Parkinson disease essential tremor and related disorders
Neurotranplantations
Regeneration Medicine
Experimental therapeutics

Publications

Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons. Jo J, Xiao Y, Sun AX, Cukuroglu E, Tran HD, Goke J, Tan ZY, Saw TY, Tan CP, Lokman H, Lee Y, Kim D, Ko HS, Kim SO, Park JH, Cho NJ, Hyde TM, Kleinman JE, Shin JH, Weinberger DR, Tan EK, Je HS, Ng HH. Cell Stem Cell. 2016 Aug 4; 19(2):248-57.
Amyloid precursor protein regulates neurogenesis by antagonizing miR-574-5p in the developing cerebral cortex. Zhang W, Selvaratnam T, Kim PJ, Yu WP, Je SH, Tan EK, Zeng L. Nat Commun. 2014 Mar 3;5:3330.
Genetics: Utility of next-generation sequencing in ataxias. Tan EK. Nat Rev Neurol. 2013 Nov;9(11):614-5.
SLC1A2 variant associated with essential tremor but not Parkinson disease in Chinese subjects. Tan EK, Foo JN, Tan L, Au WL, Prakash KM, Ng E, Ikram MK, Wong TY, Liu JJ, Zhao Y. Neurology. 2013 Apr 23;80(17):1618-9.
Rare and common LRRK2 exonic variants in Parkinson's disease. Tan EK. Lancet Neurology. 2011 Oct; 10(10):869-70.
Nonsynonymous variants in MC1R are rare in Chinese Parkinson disease cases. Foo JN et al. Ann Neurol. 2015 Jul;89(1):152-3.
A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models. Li L, Zhang CW, Chen GY, Zhu B, Chai C, Xu QH, Tan EK, Zhu Q, Lim KL, Yao SQ. Nat Commun. 2014;5:3276.
Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Angeles DC, Ho P, Chua LL, Wang C, Yap YW, Ng C, Zhou ZD, Lim KL, Wszolek ZK, Wang HY, Tan EK. Hum Mol Genet. 2014 Jun 15;23(12):3157-65.
Multicenter Analysis of Glucocerebrosidase Mutations with Parkinson’s disease. E. Sidransky et al. New England Journal Medicine 2009;361:1651-6.
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. Maraganore DM et al. JAMA. 2006;296(6):661-70.

View More +

Research Trials

Principal Investigator. A multi-centre, randomised, double-blind, placebo-and Entacapone-controlled, parallel group study of the Efficacy, Safety and tolerability of E2007 (an AMPA antagonist) in levodopa treated Parkinson’s disease patients with motor fluctuations. (PI; funded by Eisai; 2007-).
Principal Investigator. A Phase 2, 12-week, double-blind, dose-finding, placebo- controlled study to assess the efficacy and safety of a range of SCH 420814 doses (1mg BD, 2mg BD, 5mg BD, and possibly 10mg BD) in subjects with moderate to severe Parkinson’s disease experiencing motor fluctuations and dyskinesias. (PI; funded by Schering Plough; 2007 -)
Principal Investigator. A randomized, multicenter, double-blind, placebo-controlled, 18-month study of the efficacy of Xaliproden trial in patients with mild to moderate dementia of the Alzheimer’s type (PI; funded by Sanofi-aventis 2007-present)
Principal Investigator. A trial of vitamin therapy in the prevention of dementia and cognitive deterioration following stroke. BMRC(till 2010)
Principal Investigator. Rivastigmine In Vascular cognitive impairment (RIVIVE) A 24-week prospective, double blind, randomized, placebo-controlled pilot study of 9 mg/day Rivastigmine in patients with Vascular Cognitive Impairment Not Dementia to evaluate efficacy, safety and tolerability in Asian patients. (till 2010)